Closing Figures: Zentalis Pharmaceuticals Inc (ZNTL)’s Negative Finish at 4.75, Down -9.52

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $5.25 in the prior trading day, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $4.75, down -9.52%. In other words, the price has decreased by -$9.52 from its previous closing price. On the day, 4.38 million shares were traded. ZNTL stock price reached its highest trading level at $5.46 during the session, while it also had its lowest trading level at $4.66.


Our goal is to gain a better understanding of ZNTL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.19 and its Current Ratio is at 9.19. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on June 20, 2024, Downgraded its rating to Neutral and sets its target price to $5 from $28 previously.

Wedbush Downgraded its Neutral to Underperform on June 18, 2024, whereas the target price for the stock was revised from $15 to $4.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 31 ’24 when Gallagher Cam sold 9,597 shares for $11.98 per share. The transaction valued at 114,972 led to the insider holds 633,680 shares of the business.

HAUSMAN DIANA sold 3,356 shares of ZNTL for $42,353 on May 09 ’24. The Chief Medical Officer now owns 373,876 shares after completing the transaction at $12.62 per share. On Feb 12 ’24, another insider, Epperly Melissa B,, who serves as the Chief Financial Officer of the company, sold 2,573 shares for $11.44 each. As a result, the insider received 29,435 and left with 451,449 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 337312704 and an Enterprise Value of -106316144. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.32 while its Price-to-Book (P/B) ratio in mrq is 0.74. Its current Enterprise Value per Revenue stands at -2.621 whereas that against EBITDA is 0.512.

Stock Price History:

The Beta on a monthly basis for ZNTL is 1.71, which has changed by -0.8291981 over the last 52 weeks, in comparison to a change of 0.26238096 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $30.53, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is -58.38%, while the 200-Day Moving Average is calculated to be -66.90%.

Shares Statistics:

The stock has traded on average 1.10M shares per day over the past 3-months and 4002750 shares per day over the last 10 days, according to various share statistics. A total of 70.77M shares are outstanding, with a floating share count of 62.27M. Insiders hold about 12.31% of the company’s shares, while institutions hold 113.65% stake in the company. Shares short for ZNTL as of 1715731200 were 18533393 with a Short Ratio of 15.90, compared to 1713139200 on 16637859. Therefore, it implies a Short% of Shares Outstanding of 18533393 and a Short% of Float of 52.73.

Earnings Estimates

A comprehensive evaluation of Zentalis Pharmaceuticals Inc (ZNTL) is underway, with the input of 11.0 analysts contributing to its current rating.On average, analysts expect EPS of -$0.84 for the current quarter, with a high estimate of -$0.47 and a low estimate of -$0.98, while EPS last year was -$1.85. The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.52 and low estimates of -$0.99.

Analysts are recommending an EPS of between -$1.42 and -$3.9 for the fiscal current year, implying an average EPS of -$2.68. EPS for the following year is -$3.62, with 11.0 analysts recommending between -$2.78 and -$4.05.

Most Popular